• Innate Pharma co-owns intellectual property rights relating to the NKp46 receptor with INSERM, the French National Institute of Health and Medical Research
• Endorses Innate Pharma’s fruitful collaboration with leading academics on Natural Killer cell science

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, is pleased to note today that an important discovery in the field of innate immunity, made by a team led by Professor Eric Vivier, Innate Pharma’s scientific co-founder at the Center of Immunology of Marseille-Luminy (CIML), has been published in the prestigious journal Science.

> Click here for the interview of Eric Vivier and Sophie Ugolini